Innoviva Inc Dossier
Qualitative Analysis
Business overview
Innoviva, Inc. (NASDAQ: INVA) is a diversified biopharmaceutical holding company that manages a high-margin portfolio of royalty-bearing healthcare assets alongside an expanding commercial platform in critical care and infectious disease. The company's core value driver is its durable royalties portfolio, which includes significant revenue streams from long-acting respiratory therapies developed in collaboration with Glaxo Group Limited (GSK), such as Relvar/Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta. In addition to its royalty assets, Innoviva operates Innoviva Specialty Therapeutics (IST), a commercial-stage platform focused on delivering innovative therapies for drug-resistant pathogens and life-threatening conditions in hospital settings. The company also maintains strategic equity and long-term investments in promising healthcare companies, such as Armata Pharmaceuticals, Inc..
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting from a pure-play royalty company into a diversified biopharmaceutical entity built on three pillars: respiratory royalties, specialty therapeutics (IST), and strategic healthcare investments.
Expected impact: Mitigates the impact of upcoming patent expirations on legacy royalty assets (GSK's Breo and Anoro) expected around 2029-2030.
Launching Nortiva Bio as a wholly owned subsidiary to develop long-acting oral medicines using the newly acquired Lynx drug delivery platform.
Expected impact: Aims to transform daily pills into single-dose oral therapies lasting up to a month, starting with a once-monthly oral contraceptive.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired the proprietary long-acting oral drug delivery platform (Lynx) and related assets following Lyndra's operational wind-down.
Strategic Partnerships
Assists Innoviva in developing its acquisition strategy and optimizing capital allocation through the ISP Fund.
Terms: Includes advisory fees and capital allocation to the ISP Fund managed by Sarissa.
Collaborated on the pivotal Phase 3 trial and regulatory path for NUZOLVENCE® (zoliflodacin).
Terms: GARDP sponsored and led the Phase 3 clinical trial.